(Q38962913)

8 September 2017

title

Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA. (English)

1 reference

8 September 2017

1 reference

7

Alfred Morgenstern

1 reference

8 September 2017

8

Frank Bruchertseifer

1 reference

8 September 2017

Ruth A Bryan

1

1 reference

8 September 2017

Zewei Jiang

2

1 reference

8 September 2017

Thomas Jandl

3

1 reference

8 September 2017

Julius Strauss

4

1 reference

8 September 2017

Wade Koba

5

1 reference

8 September 2017

Chukwuemeka Onyedika

6

1 reference

8 September 2017

Alan L Epstein

9

1 reference

8 September 2017

Ekaterina Dadachova

10

1 reference

8 September 2017

publication date

26 August 2014

1 reference

Expert Review of Anticancer Therapy

8 September 2017

published in

1 reference

8 September 2017

volume

14

1 reference

8 September 2017

issue

10

1 reference

8 September 2017

page(s)

1243-1249

1 reference

EMT and dissemination precede pancreatic tumor formation

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Antibody-targeted radiation cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Treating cancer as an infectious disease--viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.952285

10.1586/14737140.2014.952285

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference